{"title":"[68Ga]Ga-DOTA-DP-UBI 29-41: A Novel 68Ga-Labeled Ubiquicidin 29-41 Derivative Containing d-Proline for Bacterial Infection PET Imaging","authors":"Yuhao Jiang, Peiwen Han, Yu Qian, Liyin Zhang, Yifu Sun, Guangxing Yin, Dajie Ding, Lina Diao, Ziqing Zhao, Jianyong Jiang, Junbo Zhang","doi":"10.1021/acs.molpharmaceut.6c00462","DOIUrl":null,"url":null,"abstract":"<p>Bacterial infection poses a persistent\r\nand severe threat to human\r\nhealth. Accurate differentiation between bacterial infection and sterile\r\ninflammation is critical for timely clinical treatment. In this study,\r\na novel <sup>68</sup>Ga-labeled radiotracer ([<sup>68</sup>Ga]Ga-DOTA-DP-UBI\r\n29-41) was radiosynthesized by labeling the UBI 29-41 derivative (DOTA-DP-UBI\r\n29-41) with <sup>68</sup>Ga. This radiotracer was designed by introducing <span>d</span>-proline (DP) as a linker between the ubiquicidin 29-41 (UBI\r\n29-41) targeting segment and the 1,4,7,10-tetraazacyclododecane-<em>N</em>,<em>N</em>′,<em>N</em>,<em>N</em>′-tetraacetic acid (DOTA) chelating group. The radiotracer\r\nexhibited high radiochemical purity (RCP > 98%) and favorable <em>in vitro</em> stability in normal saline at room temperature\r\nand mouse serum at 37 °C, with hydrophilic properties (Log<em>D</em> = −3.58 ± 0.04). <em>In vitro</em> bacterial experiments confirmed the specific and rapid binding of\r\nthis radiotracer to <em>Staphylococcus aureus</em>, with binding reaching equilibrium within 30 min of incubation and\r\nexhibiting concentration-dependent competitive inhibition with UBI\r\n29-41. Biodistribution studies in mouse models revealed effective\r\naccumulation of the tracer at bacterial infection sites (1.98 ±\r\n0.66% ID/g at 30 min p.i.), significantly lower renal uptake (stabilized\r\nat ∼25% ID/g) than previous <sup>68</sup>Ga-labeled UBI 29-41\r\nderivatives, and a distinct difference in uptake between bacterium-infected\r\nand sterile inflamed muscles (an infection-to-inflammation ratio of\r\n2.11 at 120 min p.i.). PET/CT imaging further confirmed that the tracer\r\ncould clearly visualize bacterial infection foci and distinguish infection\r\nfrom sterile inflammation in dual-pathology mice, with rapid blood\r\nclearance kinetics, renal metabolism, and excretion. Collectively,\r\nthese results indicate that [<sup>68</sup>Ga]Ga-DOTA-DP-UBI 29-41\r\nwill be a promising PET tracer for the specific diagnosis of bacterial\r\ninfection and differentiation from sterile inflammation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"23 8","pages":"4263–4272"},"PeriodicalIF":4.9000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.6c00462","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Bacterial infection poses a persistent
and severe threat to human
health. Accurate differentiation between bacterial infection and sterile
inflammation is critical for timely clinical treatment. In this study,
a novel 68Ga-labeled radiotracer ([68Ga]Ga-DOTA-DP-UBI
29-41) was radiosynthesized by labeling the UBI 29-41 derivative (DOTA-DP-UBI
29-41) with 68Ga. This radiotracer was designed by introducing d-proline (DP) as a linker between the ubiquicidin 29-41 (UBI
29-41) targeting segment and the 1,4,7,10-tetraazacyclododecane-N,N′,N,N′-tetraacetic acid (DOTA) chelating group. The radiotracer
exhibited high radiochemical purity (RCP > 98%) and favorable in vitro stability in normal saline at room temperature
and mouse serum at 37 °C, with hydrophilic properties (LogD = −3.58 ± 0.04). In vitro bacterial experiments confirmed the specific and rapid binding of
this radiotracer to Staphylococcus aureus, with binding reaching equilibrium within 30 min of incubation and
exhibiting concentration-dependent competitive inhibition with UBI
29-41. Biodistribution studies in mouse models revealed effective
accumulation of the tracer at bacterial infection sites (1.98 ±
0.66% ID/g at 30 min p.i.), significantly lower renal uptake (stabilized
at ∼25% ID/g) than previous 68Ga-labeled UBI 29-41
derivatives, and a distinct difference in uptake between bacterium-infected
and sterile inflamed muscles (an infection-to-inflammation ratio of
2.11 at 120 min p.i.). PET/CT imaging further confirmed that the tracer
could clearly visualize bacterial infection foci and distinguish infection
from sterile inflammation in dual-pathology mice, with rapid blood
clearance kinetics, renal metabolism, and excretion. Collectively,
these results indicate that [68Ga]Ga-DOTA-DP-UBI 29-41
will be a promising PET tracer for the specific diagnosis of bacterial
infection and differentiation from sterile inflammation.
期刊介绍:
Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development.
Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.